



Dr. Data: An Integrated Drug Repurposing Database for Identifying New Indications of FDA Approved Drugs

Cindy Wang

University of Rochester School of Medicine and Dentistry
Department of Pharmacology and Physiology

Priority Areas

Section 5. Harness Diverse Data through Information Sciences to Improve Health Outcomes: Strategic Plan for Regulatory Science

- 1. Enhance information technology infrastructure development and data mining:
- a Improve access to large, complex data sets to solve problems faster or to allow solutions of otherwise intractable problems e.g., multi-dimensional map of Salmonella;
- 2. Develop and apply simulation models for product life cycles, risk assessment, and other regulatory science uses:
- b Promote novel clinical trial design using simulation, new statistical models, and novel animal models/animal model alternatives.

Section 2. Stimulate Innovation in Clinical Evaluations and Personalized Medicine to Improve Product Development and Patient Outcomes: Strategic Plan for Regulatory Science

- 3. Identify and qualify biomarkers and study endpoints:
- b Develop and evaluate novel approaches for biomarker identification, including omics, systems biology, and high throughput methods;

Drug Repurposing

- The process of identifying new indications for previously approved drugs
- Reduced cost and the potential for rapid clinical transition versus
 \$2.5B and >14 years to develop a new drug
- Low and high throughput screening of FDA approved compound library against disease specific assays

Current Drug Repurposing Effort: New Therapeutic Uses Projects


National Center for Advancing Translational Sciences NCATS:

- NIH-Industry Partnerships Initiative AstraZeneca, Janssen, Pfizer, AbbVie, etc.
 - Launched in May 2012
 - Foster collaboration between pharmaceutical companies and the biomedical research community
- Bench-to-Clinic Repurposing Initiative
 - Funding opportunities to support pre-clinical and clinical studies

The access to large, complex drug repurposing data sets has not been readily available

Solution: Dr. Data: Collaborative Information Database on Drug Repurposing


Molecular, literature-derived and clinical data: structures and drug targets



Solution: Dr. Data: Collaborative Information Database on Drug Repurposing

- Data will be annotated using meta-analysis to allow easy access to references
- Data harmonization and transparency: OpenFDA portal offers standard data format for quick and easy application
- Dr. Data will be implemented with appropriate cybersecurity controls

Solution: Analytical Tools Embedding




Example: Common Structural Processing and Prediction

Carvedilol


Brand name: Coreg

Beta blocker used to treat congestive heart failure

New indication: under preclinical investigation



Chosen new indication: Anticancer



Amitriptyline
Brand name: Elavil

Antidepressant used to treat major depression disorder

New indication: under clinical investigation

Example: Common Structural Processing and Prediction

Carvedilol

Brand name: Coreg


Beta blocker used to treat congestive


heart failure

New indication: under preclinical investigation

Repurposing Database

Chosen new indication: Anticancer







Amitriptyline
Brand name: Elavil


Antidepressant used to treat major depression disorder


New indication: under clinical investigation

Prediction: drugs with a common tricyclic structure (similarity threshold: >90%)











❖ Why Do we Care?

- Exciting preclinical research directions, new biomarkers and novel clinical trials
- Identify potential treatment for rare diseases
- Collaboration between industry, government agencies and academia
- Insights on trends in the drug discovery field
- \$\$\$

Questions?